(SGX:584)
REG: 198403368H

Purpose of this Q&A

​

This Q&A is prepared as a public-facing explanatory note for readers of the RR-Gov™ / RDIS framework and related AI-enabled eldercare robotics research. It is intended to help government agencies, healthcare and eldercare institutions, medical professionals, engineers, governance reviewers, investors and other interested readers understand the purpose, scope, methodology, evidence boundary and interpretation limits of the RR-Gov™ / RDIS framework.

​

RR-Gov™ / RDIS should be understood as a company-led, non-peer-reviewed research paper, technical disclosure and governance-readiness planning framework for regulated deployment assessment of embodied AI humanoid eldercare robots. It should not be interpreted as clinical validation, regulatory approval, medical-device certification, product clearance, government endorsement, institutional endorsement, investment advice, commercial valuation, sales forecast or universal deployment permission.

  

1. What is RR-Gov™?
Q1. What is the purpose of the RR-Gov™ framework?

​

RR-Gov™ is a governance-readiness and institutional decision-support framework designed for the responsible assessment of embodied AI humanoid eldercare robots before controlled institutional deployment.

​

Its purpose is not to determine whether a robot can perform isolated technical functions. Instead, RR-Gov™ evaluates whether the overall deployment system — including the robot, institution, staff workflow, data infrastructure, human oversight arrangements, audit trails and post-deployment feedback mechanisms — is sufficiently supported by governance evidence for controlled institutional deployment assessment.

​

In simple terms, RR-Gov™ asks:

Is the deployment environment sufficiently governed, auditable, compliant, supervised and institutionally ready before an embodied AI eldercare robot is considered for controlled institutional use?

RR-Gov™ is therefore a governance-readiness framework. It is not regulatory approval, clinical validation, product certification, procurement approval or deployment authorisation.

​

2. What is RDIS?
Q2. What does RDIS mean?

​

RDIS means Regulated Deployment Infrastructure Score.

​

It is the core quantitative output of the RR-Gov™ framework. RDIS is designed as a weighted composite governance-readiness candidate score that helps structure the assessment of whether an embodied AI humanoid eldercare robot may be considered supportable for controlled institutional deployment assessment under defined operating conditions and evidence boundaries.

​

RDIS does not certify the robot. It does not approve deployment. It does not prove clinical effectiveness. It is a structured governance-readiness assessment indicator.

​

The correct interpretation is:

RDIS is a governance-readiness candidate score for controlled institutional deployment assessment, not a regulatory approval score or product-certification score.

 

3. What exactly does RR-Gov™ / RDIS measure?
Q3. What is the exact output measured by the RR-Gov™ / RDIS framework?

​

RR-Gov™ / RDIS measures governance-readiness support for controlled institutional deployment assessment.

​

The framework considers whether key governance conditions are sufficiently supported by evidence, including:

1. governance risk control;

2. compliance confidence;

3. AI auditability;

4. institutional deployability;

5. data governance;

6. governance-adjusted viability;

7. human oversight;

8. evidence traceability;

9. post-deployment monitoring logic.

​

RR-Gov™ / RDIS does not measure or prove:

1. regulatory approval;

2. clinical validation;

3. medical-device certification;

4. product clearance;

5. government endorsement;

6. institutional endorsement;

7. sales readiness;

8. commercial revenue;

9. investment return;

10. universal deployment readiness;

11. universal safety.

​

The output should be interpreted as:

​

a framework-derived, evidence-bounded governance-readiness candidate assessment under defined operating, institutional, data-governance and human-supervision assumptions.

​

4. What are the main components of RDIS?
Q4. What are the core dimensions assessed by RDIS?

​

The RDIS model assesses governance readiness through a weighted composite structure. The six core components are:

​

• GRI′ — Governance Risk Inversion / governance risk control indicator;

• CCF — Compliance Confidence Factor;

• AAS — AI Auditability Score;

• IDS — Institutional Deployability Score;

• DGS — Data Governance Score;

• MVS — Governance-adjusted Viability Score.

​

These components are intended to capture different aspects of responsible deployment readiness.

The purpose of using multiple components is to avoid over-reliance on a single factor, such as technical function, user acceptance, commercial interest or operational convenience.

​

The correct interpretation is:

RDIS is designed to assess a deployment system, not merely a robot product.

​

5. What does “governance-readiness” mean?
Q5. What is meant by governance-readiness in RR-Gov™?

​

Governance-readiness means that a deployment setting has sufficient governance evidence, controls and review mechanisms to support controlled institutional assessment.

​

It includes questions such as:

1. Are human oversight arrangements defined?

2. Are responsibilities clear?

3. Are compliance requirements considered?

4. Are audit trails available?

5. Are data-governance requirements addressed?

6. Are institutional workflows prepared?

7. Are risks monitored after deployment?

8. Are escalation and review mechanisms available?

​

Governance-readiness does not mean that the deployment is automatically approved. It means that the deployment may be considered supportable for further institutional review, pilot assessment or governance discussion under defined boundaries.

​

The correct interpretation is:

governance-readiness is a structured pre-deployment and deployment-assessment concept, not an approval outcome.

​

When used appropriately, RR-Gov™ / RDIS may support preliminary pilot planning, institutional risk review, workflow-readiness assessment, governance discussion and future validation design. It should be used as a structured assessment language, not as a final deployment permission.

​

6. What does the RDIS score mean?
Q6. How should a numerical RDIS result be interpreted?

​

A numerical RDIS result should be interpreted as a framework-derived governance-readiness candidate score under defined assumptions, weighting, evidence scope and stage-gate requirements.

​

For example, where a demonstration assessment produces an RDIS score above a stated threshold, the result should be read cautiously as indicating that the assessed deployment may qualify as a governance-readiness candidate for broader institutional assessment.

​

It should not be interpreted as:

• regulatory approval;

• clinical validation;

• medical-device classification;

• product certification;

• universal safety proof;

• commercial endorsement;

• investment valuation;

• universal deployment readiness.

• ​

The safe interpretation is:

an RDIS result indicates a governance-readiness candidate finding within the defined framework and evidence boundary. It does not approve deployment.

​

The detailed calculation should be read together with the related technical paper and supporting technical materials, including component definitions, evidence-to-score conversion logic, weighting structure, stage-gate interpretation and recalibration requirements.

​

7. What does the threshold mean?
Q7. Does exceeding an RDIS threshold mean the robot can be deployed?

​

No.

​

A threshold in the RDIS model is an internal governance-readiness interpretation point. It helps distinguish whether the assessed case may be considered a candidate for broader institutional assessment.

​

Exceeding a threshold does not mean:

1. the robot is approved;

2. deployment is authorised;

3. clinical use is validated;

4. regulatory clearance is obtained;

5. institution-specific approval is granted;

6. risks have been eliminated.

​

A threshold should be read together with the evidence boundary, stage-gate logic, local institutional requirements, applicable laws, data-protection obligations and human-supervision controls.

​

The correct interpretation is:

crossing an RDIS threshold may support further review, but it does not replace regulatory, institutional, clinical, ethical, data-protection or operational approval processes.

​

8. What is the stage-gate logic?
Q8. Why does RR-Gov™ use non-substitutable stage-gates?

​

RR-Gov™ uses non-substitutable stage-gate logic to prevent strengths in one area from offsetting critical weaknesses in another.

​

For example, strong technical performance, institutional interest or commercial viability should not compensate for unresolved weaknesses in:

• older-person safety;

• healthcare safety;

• compliance readiness;

• AI auditability;

• data protection;

• human oversight;

• evidence traceability;

• post-deployment monitoring.

​

The stage-gate design is intended to ensure that governance weaknesses cannot be hidden by high scores elsewhere.

​

The correct interpretation is:

non-substitutable stage-gates are designed to protect safety, compliance, auditability, data governance and human oversight from being overridden by commercial or operational strengths.

​

9. What is MVS in RR-Gov™?
Q9. Does MVS mean market value or revenue potential?

​

No.

​

In the RR-Gov™ / RDIS framework, MVS should be understood as Governance-adjusted Viability Score.

It is not a revenue score, pricing model, investment-return indicator, commercial valuation or sales forecast. It reflects whether practical adoption and scalability appear viable after minimum governance safeguards are considered.

​

MVS may consider governance-bounded factors such as:

1. user acceptance;

2. institutional acceptance;

3. facility scalability;

4. service-support readiness;

5. local business-model fit;

6. governance-fit assessment.

​

The correct interpretation is:

​

MVS is a governance-adjusted viability component, not a market-valuation or investment-return variable.

​

10. Is RR-Gov™ a clinical study?
Q10. Does RR-Gov™ constitute clinical validation?

​

No.

​

RR-Gov™ is not a clinical trial, clinical validation report, medical diagnosis study, treatment evaluation or resident outcome study.

​

It does not claim to prove:

• clinical effectiveness;

• medical treatment benefit;

• resident health improvement;

• diagnostic accuracy;

• therapeutic value;

• clinical safety clearance.

​

RR-Gov™ is a governance-readiness and deployment-assessment framework. If future studies involve identifiable residents, health data, clinical outcomes or vulnerable human participants, separate ethics review, consent procedures, data-protection safeguards and regulatory review would be required.

The safe interpretation is:

​

RR-Gov™ supports governance assessment; it does not establish clinical effectiveness.

​

11. Is RR-Gov™ a regulatory approval or product certification?
Q11. Does RR-Gov™ approve the robot for regulated deployment?

​

No.

​

RR-Gov™ / RDIS does not constitute or replace:

• regulatory approval;

• medical-device clearance;

• product certification;

• clinical evaluation;

• institutional ethics review;

• data-protection assessment;

• legal review;

• professional care judgment;

• site-specific deployment approval.

​

The framework may support planning, internal review, institutional discussion, governance reference and future validation, but it does not authorise deployment.

​

The correct interpretation is:

RR-Gov™ / RDIS provides a structured governance-readiness assessment framework. It does not constitute regulatory approval, clinical validation, medical-device certification or institutional deployment approval.

​

12. Is RR-Gov™ a legal opinion or compliance certification?
Q12. Does RR-Gov™ provide legal or compliance clearance?

​

No.

​

RR-Gov™ may help organise compliance-related assessment questions, but it is not a legal opinion, regulatory opinion, statutory clearance, compliance certificate or professional assurance report.

Any actual deployment, procurement, regulatory submission or institutional adoption should still be separately reviewed by appropriate legal, regulatory, clinical, technical, operational and data-protection professionals.

​

The safe interpretation is:

RR-Gov™ supports structured compliance-readiness discussion, but it does not replace legal advice, regulatory review or institutional approval.

​

13. Is RR-Gov™ a literature review or prior-art search?
Q13. How is RR-Gov™ related to public-source and prior-art review?

​

RR-Gov™ is not merely a literature review. It is a governance-readiness framework supported by public-source and prior-art review.

​

The related public-source and prior-art review helps position RR-Gov™ / RDIS within existing literature, policy, standards, AI governance, robotics governance and eldercare deployment discussions.

​

The prior-art review does not prove absolute global uniqueness. Rather, it supports a cautious research-positioning statement that no highly identical public integrated governance-readiness framework was identified within the reviewed public-source scope at the time of the search.

​

The correct interpretation is:

public-source search supports cautious framework positioning; it does not constitute legal confirmation of global uniqueness.

​

14. What does “first-definition-type” mean?
Q14. Does “first-definition-type” mean legally confirmed world-first?

​

No.

​

“First-definition-type” means that, based on public-source searches conducted to date and within the reviewed scope, RR-Gov™ / RDIS may be positioned as an early structured framework that defines and integrates governance-readiness assessment for regulated deployment of embodied AI humanoid eldercare robots.

​

It does not mean:

1. legally confirmed world-first;

2. globally unique without qualification;

3. regulatory-recognised first framework;

4. academically final world-first determination;

5. independent third-party validation.

​

The safe wording is:

To the best of the Group’s knowledge, and based on public-source searches conducted to date, RR-Gov™ / RDIS may be described as a first-definition-type and among the earliest identified integrated governance-readiness assessment frameworks for the regulated deployment of embodied AI humanoid eldercare robots.

​

15. What are the early integrated framework characteristics of RR-Gov™ / RDIS?
Q15. Can RR-Gov™ / RDIS be described as having early integrated framework characteristics?

​

Yes, cautiously.

​

RR-Gov™ / RDIS may be described as having early integrated framework characteristics within the reviewed public research landscape, based on public-source searches conducted to date and subject to the stated evidence boundaries.

​

These characteristics include:

1. integrated weighted governance-readiness scoring;

2. non-substitutable stage-gate logic;

3. governance-card interpretation;

4. regulated deployment infrastructure assessment;

5. embodied AI eldercare robotics context;

6. human oversight, auditability and data-governance integration.

​

This should not be interpreted as an absolute legal, regulatory or academic confirmation of global uniqueness.

​

The correct interpretation is:

“early integrated framework characteristics” is a cautious research-positioning expression, not an absolute world-first claim.

​

16. How should government agencies and eldercare institutions read RR-Gov™?
Q16. What is the relevance for public-sector and institutional readers?

​

Government agencies and eldercare institutions may read RR-Gov™ / RDIS as a structured framework for thinking about responsible institutional deployment assessment of embodied AI humanoid eldercare robots.

​

It may support discussion on:

• governance-readiness review;

• pilot design;

• human oversight;

• auditability;

• data governance;

• evidence collection;

• institutional workflow integration;

• post-deployment monitoring;

• escalation and review mechanisms;

• responsible adoption safeguards.

​

It should not be used as a substitute for official policy decisions, regulatory assessment, procurement due diligence, clinical evaluation, data-protection review or institution-specific approval.

​

17. How should engineers read RR-Gov™?
Q17. What does RR-Gov™ mean for engineering and technical teams?

​

For engineers and technical teams, RR-Gov™ highlights that responsible deployment of embodied AI eldercare robots is not only a question of technical capability. It is also a question of whether the system can be made auditable, supervised, monitored, documented and integrated into institutional workflows.

Engineering teams may use RR-Gov™ to consider:

1. audit logs;

2. system traceability;

3. human override;

4. safety boundaries;

5. data minimisation;

6. data retention;

7. model behaviour review;

8. incident escalation;

9. post-deployment monitoring;

10. integration with care workflows;

11. role clarity between robot, staff and institution.

​

The framework encourages technical teams to design systems that are not only functional, but also governable, reviewable and institutionally accountable.

​

18. How should medical and care professionals read RR-Gov™?
Q18. What does RR-Gov™ mean for medical and care professionals?

​

Medical and care professionals should interpret RR-Gov™ as a governance-readiness and safety-boundary framework, not as a replacement for professional care judgment.

​

The framework may help care professionals consider:

• whether human supervision is clearly defined;

• whether the robot’s role is bounded;

• whether escalation pathways exist;

• whether staff remain responsible for care decisions;

• whether data and alerts are reviewable;

• whether older-person safety is protected;

• whether institutional workflow is prepared;

• whether post-deployment monitoring is required.

​

RR-Gov™ does not claim that robots replace human empathy, nursing judgment, clinical assessment, emergency response, medical responsibility or professional accountability.

​

19. Why is RR-Gov™ relevant to investors and shareholders?
Q19. Why does RR-Gov™ matter if it is not regulatory approval or commercial validation?

​

RR-Gov™ is relevant because it provides a structured research foundation for responsible AI-enabled eldercare robotics deployment assessment.

​

Its value lies in helping the Group develop an auditable, explainable and reviewable institutional deployment language for responsible AI-enabled eldercare robotics.

​

Its relevance also lies in:

1. creating a governance-readiness assessment language;

2. clarifying how institutional deployment readiness may be assessed;

3. reducing the risk of unsupported commercial or deployment claims;

4. supporting future engagement with institutions, regulators, healthcare operators and technology partners;

5. strengthening the company’s research positioning in responsible AI, auditability, data governance and human oversight;

6. supporting future peer-reviewed research, institutional pilots and responsible commercial evaluation.

 

However, RR-Gov™ should not be presented as proof of revenue, regulatory approval, guaranteed deployment, clinical approval, confirmed adoption or commercial success.

​

The safe shareholder-related interpretation is:

RR-Gov™ provides a structured governance-readiness research foundation for future institutional engagement and responsible commercial evaluation. It is not itself a commercialisation result, sales forecast or deployment approval.

​

20. Can RR-Gov™ be submitted to a peer-reviewed journal later?
Q20. Can the framework later be developed into a journal manuscript?

​

Potentially yes, subject to the target journal’s policies.

​

Any future journal submission should:

1. disclose any prior public company website version or DOI;

2. explain that the prior version was a non-peer-reviewed technical preprint or technical disclosure;

3. substantially revise and strengthen the manuscript;

4. add further scholarly value;

5. include stronger methodology, literature positioning, standards anchoring, validation design, sensitivity analysis or independent review where applicable;

6. comply with the journal’s prior-publication and preprint policy.

​

The company website version should not describe itself as a journal article, accepted manuscript, final publication, regulatory approval or product-clearance document.

​

21. What are the main limitations of RR-Gov™ / RDIS?
Q21. What should readers keep in mind?

​

The key limitations are:

1. the current version is not independently peer-reviewed unless later accepted by a journal;

2. RDIS is a framework-derived governance-readiness candidate score, not an approval decision;

3. the demonstration result depends on defined assumptions, evidence scope and weighting;

4. local institutional review remains necessary;

5. regulatory, clinical, legal and data-protection review remain separate;

6. evidence quality depends on source-record completeness and reviewability;

7. stage-gate thresholds require careful interpretation;

8. multi-site validation remains necessary;

9. longer deployment monitoring is required;

10. independent assessor review would strengthen credibility;

11. clinical effectiveness and resident outcome improvement are not established by RR-Gov™ alone;

12. commercial viability, revenue generation and financial performance are not established by RR-Gov™ alone.

These limitations should be treated as part of responsible public disclosure, not as issues to hide.

​

22. What should not be concluded from RR-Gov™ / RDIS?
Q22. What interpretations should readers avoid?

​

Readers should avoid concluding that:

1. RR-Gov™ / RDIS is regulatory approval;

2. RDIS is a product-certification score;

3. crossing a threshold automatically permits deployment;

4. the robot is clinically validated;

5. the company has achieved regulatory clearance;

6. the framework guarantees commercialisation;

7. the framework proves resident outcome improvement;

8. the framework proves commercial success;

9. the framework is legally confirmed as globally unique;

10. the result applies to all institutions without local review;

11. the result is a final peer-reviewed conclusion, unless later accepted and published by a peer-reviewed journal.

​

Preferred interpretation:

RR-Gov™ / RDIS is a framework-derived, evidence-bounded governance-readiness and regulated deployment assessment model under defined assumptions, stage-gate logic and institutional review boundaries.

​

23. What is the safest one-sentence summary?
Q23. How should RR-Gov™ / RDIS be summarised?

​

The safest one-sentence summary is:

RR-Gov™ / RDIS is a company-developed, non-peer-reviewed governance-readiness research and planning framework that uses a weighted RDIS candidate score and non-substitutable stage-gate logic to assess controlled institutional deployment readiness of embodied AI humanoid eldercare robots under defined evidence and supervision boundaries, but it does not constitute regulatory approval, clinical validation, medical-device certification, product clearance, commercial valuation or universal deployment permission.

 

Public-Facing Conclusion

​

RR-Gov™ / RDIS is proposed as a structured governance-readiness and regulated deployment assessment framework for embodied AI humanoid eldercare robots. It is intended to support responsible discussion among care institutions, engineers, healthcare professionals, governance reviewers, researchers, public-sector stakeholders and interested investors.

​

Its contribution is to translate governance risk control, compliance confidence, AI auditability, institutional deployability, data governance and governance-adjusted viability into a framework-level, weighted and stage-gated governance-readiness candidate assessment.

​

Any RDIS result should be interpreted only within its stated assumptions, evidence boundary, weighting structure and stage-gate logic. It indicates a possible governance-readiness candidate finding for further assessment, not regulatory approval, clinical validation, product certification, commercial valuation, government endorsement, institutional endorsement or universal deployment readiness.

 

Final Public Interpretation Statement

​

RR-Gov™ / RDIS should be understood as:

a framework-level governance-readiness and regulated deployment assessment model, not regulatory approval, clinical validation, product certification, deployment authorisation or commercial valuation.